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Abstract 
Background: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic 
urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as 
a proto‑oncogene, which is overexpressed in various human cancers. Since there are controversial reports about the 
role of Src in bladder cancer, we evaluated the efficacy of the Src kinase inhibitor dasatinib in the urothelial bladder 
cancer cell line RT112 and its gemcitabine‑resistant sub‑line RT112rGEMCI20 in vitro and in vivo.
Methods: RT112 urothelial cancer cells were adapted to growth in the presence of 20 ng/ml gemcitabine 
(RT112rGEMCI20) by continuous cultivation at increasing drug concentrations. Cell viability was determined by MTT 
assay, cell growth kinetics were determined by cell count, protein levels were measured by western blot, and cell 
migration was evaluated by scratch assays. In vivo tumor growth was tested in a murine orthotopic xenograft model 
using bioluminescent imaging.
Results: Dasatinib exerted similar effects on Src signaling in RT112 and RT112rGEMCI20 cells but RT112rGEMCI20 cells 
were less sensitive to dasatinib‑induced anti‑cancer effects (half maximal inhibitory concentration (IC50) of dasatinib 
in RT112 cells: 349.2 ± 67.2 nM; IC50 of dasatinib in RT112rGEMCI20 cells: 1081.1 ± 239.2 nM). Dasatinib inhibited 
migration of chemo‑naive and gemcitabine‑resistant cells. Most strikingly, dasatinib treatment reduced RT112 tumor 
growth and muscle invasion in orthotopic xenografts, while it was associated with increased size and muscle‑invasive 
growth in RT112rGEMCI20 tumors.
Conclusion: Dasatinib should be considered with care for the treatment of urothelial cancer, in particular for therapy‑
refractory cases.
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Background
Bladder cancer is the second most common cancer of the 
genitourinary tract. First-line therapy regimens for meta-
static disease include gemcitabine and cisplatin (GC) as 
standard of care resulting in response rates of 40–70 %. 
However, resistance acquisition is common and the 
median survival is unsatisfactory being 12–14 months [1, 
2]. Effective second-line therapies are missing [3, 4].
The c-Src proto-oncogene has been strongly implicated 
in the development, growth, progression, and metastasis 
of a number of human cancers including those of colon, 
breast, pancreas, and brain [5, 6]. Several clinical tri-
als showed antitumoral activity of Src family inhibitor 
dasatinib in different cancer entities [7, 8]. The role of Src 
kinase as drug target in bladder cancer is controversial. 
Src inhibition caused anti-cancer effects in some bladder 
cancer cell lines (including RT112) and animal models [9, 
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10]. In other studies, however, Src inhibition increased 
bladder cancer cell migration and metastasis forma-
tion [11, 12]. A recently published phase II trial did not 
demonstrate clinical benefit of single-agent dasatinib in 
unselected patients with muscle-invasive urothelial carci-
noma of the bladder [13].
Here, we investigated the effects of dasatinib on RT112 
urothelial bladder cancer cells and RT112 cells with 
acquired resistance to gemcitabine (RT112rGEMCI20) in 
cell culture and in an orthotopic xenograft model.
Methods
Drugs
Gemcitabine (Gemzar®) was obtained from Lilly (Indian-
apolis, IN, USA). Dasatinib was obtained from Absource 
Diagnostics (München, Germany).
Cell lines and lentiviral transduction
RT112 cells were obtained from the American Type Cul-
ture Collection (Manassas, VA, USA). Cells were grown 
in Iscove’s modified Dulbecco’s medium supplemented 
with 10 % fetal calf serum (FCS, Gibco, Karlsruhe, Ger-
many). RT112 cells were adapted to growth in presence 
of 20 ng/ml gemcitabine by continuous cultivation in the 
presence of increasing drug concentrations as previously 
described [14] resulting in the gemcitabine-resistant 
subline RT112rGEMCI20. For in vivo studies, RT112 and 
RT112rGEMCI20 cell lines underwent transduction with 
a lentiviral construct carrying the luciferase firefly gene 
for in  vivo imaging resulting in cell lines RT112luc and 
RT112rGEMCI20luc. The luciferase plasmid contained 
a blasticidin-resistance gene enabling positive selection 
with 10  mg/ml blasticidin (Life Technologies GmbH, 
Darmstadt, Germany). Cell lines were controlled for 
in vitro luciferase activity and cell number was correlated 
with bioluminescence using the Xenogen IVIS Spectrum 
(Caliper Lifesciences, Hopkinton, MA, USA) as previ-
ously described [15].
Viability assay
Cell viability was tested by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye reduc-
tion assay after 120  h incubation modified as described 
before [16]. All experiments were performed at least in 
triplicate.
Cell proliferation
At day 0, 4000 cells/ml were plated in culture flasks. Cell 
numbers were determined every 24  h for 6 consecu-
tive days using the automated cell counter Countess® 
(Life Technologies GmbH) after trypan blue staining. 
Doubling time (DT) was calculated using the formula 
DT = culture time/cell doubling. Cell doubling = ln(Nf/
Ni)/ln2, where Ni represents seeded cells number and Nf 
the harvested cells number [17]. All experiments were 
performed at least in triplicate.
Western blot
Cells were lysed in Triton X sample buffer and separated 
by sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE). Proteins were detected using specific 
antibodies against β-actin (#A5441, Sigma-Aldrich, St. 
Louis, MO, USA), Src (#2123, Cell Signaling, Cambridge, 
UK), phosphorylated Src (Tyr416, #2101, Cell Signal-
ing), Akt (#9272, Cell Signaling), and phosphorylated 
Akt (Thr308, #2965, Cell Signaling and Ser473, #04-736, 
EMD-Millipore, Billerica, MA, USA). Protein bands were 
visualized by enhanced chemiluminescence using a com-
mercially available kit (GE Healthcare, Little Chalfont, 
UK). Pixel density of western blots is given in percentage 
compared to untreated cell line (100 %). All experiments 
were performed at least in triplicate.
Wound healing migration assay
RT112 or RT112rGEMCI20 cells were plated onto six-well 
plates and allowed to form a confluent monolayer. The 
cell monolayer was then scratched in a straight line to 
make a ‘scratch wound’ with a 0.2 ml pipette tip and the 
cell debris was removed by washing the cells with phos-
phate-buffered saline. Images of the closure of the scratch 
were captured at 0, 6, and 24 h. Quantification of wound 
repair was obtained from six measurements of every 
treatment from three independent experiments.
Ethics statement
All animal procedures were performed according to the 
guidelines of the Canadian Council on Animal Care and 
approved by the Institutional Review Board of the Uni-
versity of British Columbia (approval #A10-0295).
Intramuscular orthotopic xenograft murine model
Animal experiments were performed as described previ-
ously [15, 18]. Mice were subdivided into four treatment 
arms: RT112luc control treatment (n  =  15), RT112luc 
dasatinib treatment (n  =  15), RT112rGEMCI20luc con-
trol treatment (n =  15), and RT112rGEMCI20luc dasat-
inib treatment (n  =  14). Six-week-old male nude mice 
(Harlan Laboratories, Indianapolis, IN, USA) were anes-
thetized with isoflurane (2 Vol.  %) and analgesia was 
provided by subcutaneous injection with buprenorphine 
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and meloxicam (Boehringer Ingelheim, Burlington, ON, 
Canada). After disinfection of the abdominal wall with 
chlorhexidine, a low transverse laparotomy was made 
and the urinary bladder was extracorporealized. 50 μl of 
a cell suspension containing 5 × 105 cells were directly 
injected into the bladder wall. The incision was closed 
with suture. Bioluminescence was used to quantify 
tumor burden and was measured on the xenogen IVIS 
spectrum imaging system after intraperitoneal injec-
tion of 200 μg/kg luciferin (Caliper Lifesciences). Images 
were taken at 10 and 14 min after luciferin injection and 
the average counts were used for statistical analysis. 
Evaluation of bioluminescence in this orthotopic model 
showed that 10  ×  108 photons/s correlate to 10  mm3 
tumor volume [19]. Bioluminescence imaging was per-
formed on day 5 after tumor inoculation and mice were 
divided into equal treatment groups based on tumor 
burden. Treatment started the following day and imag-
ing was repeated every 4 days. Necropsy was performed 
after 4 weeks. Dasatinib was administered by oral gavage 
with an in  vivo relevant dose of 20  mg/kg body weight 
(BW) twice daily [20] in sodium citrate/citric acid 
(Sigma-Aldrich, St. Louis, MO, USA). Vehicle treatment 
was prepared and administered in an identical manner, 
but without dasatinib. All experiments were performed 
at least in triplicate.
Haematoxylin and eosin staining (H&E)
All samples were fixed in buffered 4 % formalin (pH7.4) 
and embedded in paraffin. We used standard procedures 
for deparaffinization and rehydration. Slides were cut at 
a microtome into 3  μm slices. H&E staining were per-
formed according to standard.
Statistical analysis
Results are expressed as mean ±  standard deviation (SD) 
of at least three independent experiments. For statistical 
analysis student´s t test, analysis of variance (ANOVA), and 
Student–Newman–Keuls-Test were performed whenever 
applicable. Significance was defined at values of p ≤ 0.05.
Results
Growth characteristics and sensitivity to gemcitabine 
of RT112 and RT112rGEMCI20 cells
RT112 and RT112rGEMCI20 cells showed similar 
growth kinetics with doubling times of 23.28  ±  2.88  h 
in RT112 cells and 25.2  ±  3.12  h in RT112rGEMCI20 
cells. Transduction with the luciferase plasmid, which 
is needed to monitor in  vivo tumor growth, did not 
alter cell growth kinetics (doubling time RT112luc: 
24.72  ±  5.04  h; doubling time RT112rGEMCI20luc: 
27.36  ±  3.6  h) (Fig.  1a; Table  1). RT112rGEMCI20 cells 
(IC50  =  125.40  ±  29.78  ng/ml) displayed a 77-fold 
increased resistance to gemcitabine compared to paren-
tal RT112 cells (IC50  =  1.63  ±  0.55  ng/ml). There was 
a similar sensitivity to gemcitabine in the luciferase-
transduced cell lines RT112luc and RT112rGEMCI20luc 
compared to RT112 and RT112rGEMCI20 [RT112luc 
(IC50: 1.94  ±  0.24) and RT112rGEMCI20luc (IC50: 
114.39 ± 14.52)] (Table 1).
Growth characteristics of RT112luc and RT112rGEMCI20luc 
tumors in vivo
In vivo, growth of RT112luc and RT112rGEMCI20luc 
tumors was investigated in an established murine ortho-
topic xenograft model [15, 18, 19, 21]. RT112rGEMCI-
20luc cells were used for the first time in this orthotopic 
model. Nude mice received either 5 ×  105 RT112luc or 
RT112rGEMCI20luc cells directly injected into the blad-
der wall. Tumor take rates were 90 % (27 out of 30 ani-
mals) for RT112luc cells and 100 % (30 out of 30 animals) 
for RT112rGEMCI20luc cells. RT112rGEMCI20luc xeno-
grafts grew substantially slower than RT112luc xeno-
grafts resulting in a 6-fold smaller average tumor volume 
at day 25 (p < 0.0001) (Fig. 1b).
In vitro effects of dasatinib on RT112 and RT112rGEMCI20 
cells
RT112rGEMCI20 cells (IC50: 1081.1 ± 239.2 nM) showed 
a 3.1-fold decreased sensitivity to dasatinib compared to 
parental RT112 cells (IC50: 349.2 ±  67.2  nM). The con-
centration-dependent drug response from a representa-
tive experiment is shown in Fig. 1c.
In cell culture, dasatinib caused in RT112 and in 
RT112rGEMCI20 cells a dose-dependent reduction of 
Src phosphorylation. Phosphorylation of Akt (Thr308) 
was also reduced in both cell lines with a stronger inhibi-
tion in the chemo-naive cell line. No inhibition of pAkt 
(Ser473) was detected (Fig. 2a, b).
Since Src inhibition was described to increase migra-
tion in urothelial cancer [12], we evaluated migratory 
behavior using a wound healing scratch assay in RT112 
and RT112rGEMCI20 cells with and without dasatinib 
treatment. Results indicated a similar time-dependent 
migration inhibition in response to dasatinib in RT112 
and RT112rGEMCI20 cells resulting in >60  % inhibition 
of migration in both cell lines relative to untreated con-
trol (p < 0.0001) (Fig. 2c, d).
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Effects of dasatinib treatment in RT112luc 
and RT112rGEMCI20luc xenografts
Dasatinib treatment using 20  mg/kg twice daily [20] 
caused a reduction of RT112luc xenograft size by 39  % 
(p  =  0.036) relative to untreated control at day 25. In 
contrast, dasatinib treatment induced a 4-fold increase 
in RT112rGEMCI20luc tumor size compared to vehi-
cle treated RT112rGEMCI20luc xenografts at day 25 
(p < 0.001) (Fig. 3).
Tumors were sampled and H&E staining was per-
formed at day 25. Untreated RT112luc tumors displayed 
muscle-invasive growth (pT2) (Fig.  4a). In contrast, no 
signs of muscle-invasive growth (pT1) were detected in 
dasatinib-treated RT112luc tumors (Fig.  4b). The oppo-
site pattern was observed in RT112rGEMCI20luc tumors. 
Untreated RT112rGEMCI20luc tumors did not show 
muscle-invasive growth (pT1) (Fig.  4c), while dasatinib-
treated RT112rGEMCI20luc xenografts displayed muscle 
invasive growth (pT2) (p  <  0.001). In dasatinib-treated 
RT112rGEMCI20luc xenografts, the bladder muscle was 
completely infiltrated by the tumor, and the bladder wall 
was not clearly visible anymore (Fig. 4d).
Fig. 1 a Growth kinetics of the urothelial cancer cell line RT112 and its gemcitabine‑resistant sub‑line RT112rGEMCI20 in cell culture. On day 0, both 
cell lines started with 4000 cells per milliliter. b In vivo growth kinetics of RT112luc and RT112rGEMCI20luc tumors in an orthotopic nu/nu mouse 
xenograft model as determined by bioluminescence. 10 × 108 photons/s correlate to 10 mm3 tumor volume (21). c Concentration‑dependent 
effects of dasatinib on the viability of the urothelial cancer cell line RT112 and its gemcitabine‑resistant sub‑line RT112rGEMCI20 as indicated by MTT 
assay after 120 h of incubation
Table 1 Comparison of  growth kinetics (doubling time) 
of  RT112, RT112rGEMCI20, RT112luc, and  RT112rGEM-
CI20luc cell lines and  cell viability (IC50) after  treatment 
with gemcitabine
Cell line Doubling time (h) IC50 (ng/ml)
RT112 23.28 ± 2.88 1.63 ± 0.55
RT112rGEMCI20 25.2 ± 3.12 125.40 ± 29.78
RT112luc 24.72 ± 5.04 1.94 ± 0.24
RT112rGEMCI20luc 27.36 ± 3.6 114.39 ± 14.52
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Discussion
In this study, we compared the effects of the Src inhibi-
tor dasatinib on the urothelial cancer cell line RT112 and 
its gemcitabine-resistant sub-line RT112rGEMCI20 in cell 
culture and in an orthotopic bladder cancer xenograft 
model in mice.
In cell culture, both cell lines displayed similar growth 
kinetics. Dasatinib inhibited Src phosphorylation in 
RT112 and RT112rGEMCI20 cells at low nanomolar 
concentrations similar to those that had already been 
described to affect Src phosphorylation [9]. While dasat-
inib had previously been shown to interfere with the 
phosphorylation of Akt (Thr308 and Ser473) in squa-
mous cell lung cancer [22], we only detected inhibition 
of phosphorylation of Akt (Thr308). The reasons for this 
may be the consequence of cell type-specific differences 
Fig. 2 a Representative western blots showing cellular levels of Src, pSrc, Akt, pAkt, and β‑actin in RT112 and RT112rGEMCI20 cells after 24 h incu‑
bation with dasatinib. b Pixel density of western blots is given in percentage compared to untreated cell line (100 %). One of three independent 
experiments is shown here. *p ≤ 0.05 vs untreated cell line. c Wound healing migration assay. Effects of dasatinib (100 nM) treatment on RT112 or 
RT112rGEMCI20 cells were evaluated. Images of the closure of the scratch were captured at 0, 6, and 24 h. Representative images of scratch wound 
assays were shown (magnification ×100). d Quantification of wound repair was obtained from six measurements of every treatment from three 
independent experiments
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between the investigated models. Although dasatinib 
exerted similar effects on Src signaling in RT112 and 
RT112rGEMCI20 cells, its effects on cell viability differed 
between the two cell lines. The effective concentrations 
of dasatinib in RT112 cells (IC50 of 349.2  ±  67.2  nM) 
were in the range of those previously described for 
the treatment of urothelial cancer cells [9]. However, 
in RT112rGEMCI20 cells the IC50 value was about 
3-fold higher (1081.1  ±  239.2  nM). This suggests that 
RT112rGEMCI20 cells have acquired resistance mecha-
nisms that interfere with antitumoral effects of dasatinib 
downstream of Src signaling. In accordance, dasatinib 
treatment resulted in reduced inhibition of the phospho-
rylation of the Src downstream kinase Akt (Thr 308) in 
RT112rGEMCI20 cells compared to RT112 cells.
In nude mice, RT112rGEMCI20luc cells formed about 
6-fold smaller tumors than RT112luc cells. The reasons 
for this remain unclear. However, it is known that differ-
ent cell lines may differ in their interaction with the tissue 
environment in animal models resulting in discrepancies 
in the growth kinetics [23, 24].
The most striking differences were found after 
oral dasatinib treatment of mice bearing orthotopic 
RT112luc or RT112rGEMCI20luc xenografts. Dasatinib 
treatment of RT112luc bladder tumors resulted in a sig-
nificant reduction of tumor size relative to untreated 
control. In contrast, dasatinib treatment of RT112rGEM-
CI20luc bladder tumors resulted in a dramatic increase 
of tumor growth. In addition, the dasatinib treatment 
prevented muscle-invasive growth of RT112luc xeno-
grafts, but strongly induced muscle-invasive growth 
of RT112rGEMCI20luc xenografts. The mechanistic 
reasons underlying this discrepancy remain elusive. 
Wu et  al. [11] had reported that loss of Src increases 
metastasis formation in a bladder cancer model. Simi-
lar to this report, Thomas et  al. [12] showed that Src 
enhances urothelial cancer cell migration and metasta-
sis formation. However, dasatinib inhibited RT112 and 
RT112rGEMCI20 cell migration in a similar manner, 
similarly to other studies that reported on the effects of 
Src inhibition on cancer cell migration in models from 
different cancer entities [25–28]. Therefore, it seems 
unlikely that the dasatinib-induced increased invasive 
growth of RT112rGEMCI20luc cells in the xenograft 
model may be caused by dasatinib-induced enhanced 
RT112rGEMCI20luc cell migration.
Fig. 3 Tumor growth kinetics of murine orthotopic a RT112luc and b RT112rGEMCI20luc xenografts. Dasatinib was given per oral gavage at a dose 
of 20 mg/kg body weight (BW) twice daily. Control animals were vehicle‑treated in the same way. 10 × 108 photons/s correlate to 10 mm3 tumor 
volume (21). c Representative photographs of treated and untreated RT112luc and RT112rGEMCI20luc xenografts with fluorescent bladder tumors
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Conclusions
We present the first study that investigated the effects of 
dasatinib on urothelial cancer cells with acquired resistance 
to gemcitabine. In cell culture, gemcitabine-resistant RT112 
cells were less sensitive to dasatinib than parental RT112 
cells. Notably, parental RT112 cells and gemcitabine-
resistant RT112 cells displayed an unexpected opposite 
response to dasatinib in an orthotopic xenograft model in 
mice. While dasatinib inhibited tumor growth and muscle 
invasion by parental RT112 cells, it increased tumor growth 
and muscle invasion by gemcitabine-resistant RT112 cells. 
Thus, our data do not generally support the use of dasatinib 
for the treatment of urothelial cancer, in particular not for 
therapy-refractory cases after first-line chemotherapy with 
gemcitabine. However, further studies will need to show 
whether similar effects are obtained in additional models 
of (acquired gemcitabine resistance in) urothelial cancer. If 
such studies suggested that some urothelial cancer diseases 
may benefit from dasatinib therapy, biomarkers would need 
to be identified that enable the prediction of the response of 
individual urothelial cancer diseases to dasatinib.
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